Renal: Research Studies

29 Related Result(s)

1. A Phase 1, open-label study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment

   Pharmacokinetic (PK) Part (Primary Objectives) (Cycle 1):1. To compare the plasma PK profile of TAS-102 (FTD, FTY, and TPI) in advanced solid tumor patients...

2. A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

   This phase II trial studies how well axitinib and nivolumab works in treating participants with TFE/translocation renal cell carcinoma that cannot be removed...

3. A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

   This phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney...

4. Phase II Trial of the PARP1 Inhibitor, Niraparib, in BAP1 and other DNA Damage Response (DDR) Pathway Deficient Neoplasms

   The primary objective is to determine the response rate for subject with mutations in BAP1 and other genes...

5. Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

   This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come...

6. Phase II Trial of Niraparib in BAP1 and other DDR Deficient Neoplasms (UF-STO-ETI-001)

   The purpose of this study is to investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage...

7. Targeted Therapy Directed by Genetic Testing in Advanced Refractory Solid Tumors or Lymphomas

   This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have...

8. A Phase II Trial of TAS-102 (Lonsurf) in Patients With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma After Progression Through First Line Chemotherapy

   The primary objective is to evaluate the activity of TAS-102 in previously treated metastatic and locally...

9. Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects with Acute Myeloid Leukemia (AML) that is Refractory to or Relapsed after Standard Induction Therapy

   This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of...

10. Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta (Zone 2) (SSB 11-02)

    Composite of the following events through one month: initiation of the index endovascular procedure following the debranching procedure, device technical...

Pages